Protagonist Therapeutics (PTGX) Retained Earnings (2017 - 2025)
Protagonist Therapeutics (PTGX) has disclosed Retained Earnings for 9 consecutive years, with $641000.0 as the latest value for Q4 2025.
- Quarterly Retained Earnings rose 881.71% to $641000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $641000.0 through Dec 2025, up 881.71% year-over-year, with the annual reading at $641000.0 for FY2025, 881.71% up from the prior year.
- Retained Earnings hit $641000.0 in Q4 2025 for Protagonist Therapeutics, up from -$426.3 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $641000.0 in Q4 2025 to a low of -$608.9 million in Q2 2023.
- Historically, Retained Earnings has averaged -$268.8 million across 5 years, with a median of -$362.3 million in 2021.
- Biggest five-year swings in Retained Earnings: tumbled 1303839.39% in 2022 and later soared 881.71% in 2025.
- Year by year, Retained Earnings stood at -$299000.0 in 2021, then plummeted by 179416.72% to -$536.8 million in 2022, then skyrocketed by 99.98% to -$105000.0 in 2023, then increased by 21.9% to -$82000.0 in 2024, then skyrocketed by 881.71% to $641000.0 in 2025.
- Business Quant data shows Retained Earnings for PTGX at $641000.0 in Q4 2025, -$426.3 million in Q3 2025, and -$386.9 million in Q2 2025.